Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst David Larsen maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $20 to $16.
Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and...
SEC
Evolent Health (NYSE:EVH) raises FY2025 sales outlook from $1.850 billion-$1.880 billion to $1.870 billion-$1.880 billion vs $1...
Evolent Health (NYSE:EVH) sees Q4 sales of $462.000 million-$472.000 million vs $481.406 million analyst estimate.
Evolent Health (NYSE:EVH) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.11 b...
BTIG analyst David Larsen reiterates Evolent Health (NYSE:EVH) with a Buy and maintains $20 price target.
